The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
2011

Sunitinib and Thyroid Atrophy in Kidney Cancer Patients

Sample size: 17 publication 10 minutes Evidence: moderate

Author Information

Author(s): Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K

Primary Institution: Hokkaido University Graduate School of Medicine

Hypothesis

Does sunitinib treatment lead to thyroid atrophy in patients with metastatic renal cell carcinoma?

Conclusion

Sunitinib treatment frequently causes thyroid atrophy and may lead to irreversible hypothyroidism.

Supporting Evidence

  • The median reduction rate in thyroid volume was 30% in all patients.
  • Nine patients developed hypothyroidism during treatment.
  • Histological evaluation showed atrophy of thyroid follicles.
  • Half of the patients in the high reduction rate group exhibited transient TSH suppression.

Takeaway

This study found that a medicine called sunitinib can shrink the thyroid gland in some cancer patients, which can make them feel tired and cold because their body isn't making enough thyroid hormone.

Methodology

Thyroid volume and function were measured at baseline, during treatment, and post-treatment, with histological evaluation in autopsied patients.

Potential Biases

Potential bias due to the observational nature of the study and the lack of a control group.

Limitations

The study had a small sample size and was observational, which may limit the generalizability of the findings.

Participant Demographics

Median age was 62 years, with a mix of previous treatments including IFN-α.

Statistical Information

P-Value

0.083

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606029

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication